Evidence map›Paper›PMID 28405507›Full record

ReviewOncoimmunology

A review of the importance of immune responses in luminal B breast cancer.

Delia J Nelson, Briony Clark, Kylie Munyard, Vincent Williams, David Groth, Jespal Gill, Henry Preston, Arlene Chan

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Multi-omic Profiling of Recurrence Risk Across Breast Cancer Subtypes.medRxiv : the preprint server for health sciences · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Delia J NelsonSchool of Biomedical Sciences, Curtin University, Bentley, Perth, WA, Australia; CHIRI Biosciences, Curtin University, Perth, WA, Australia.
Briony ClarkSchool of Biomedical Sciences, Curtin University, Bentley, Perth, WA, Australia; CHIRI Biosciences, Curtin University, Perth, WA, Australia.
Kylie MunyardSchool of Biomedical Sciences, Curtin University, Bentley, Perth, WA, Australia; CHIRI Biosciences, Curtin University, Perth, WA, Australia.
Vincent WilliamsSchool of Biomedical Sciences, Curtin University , Bentley, Perth, WA, Australia.
David GrothSchool of Biomedical Sciences, Curtin University, Bentley, Perth, WA, Australia; CHIRI Biosciences, Curtin University, Perth, WA, Australia.
Jespal GillWestern Diagnostics Pathology , Myaree, Perth, WA, Australia.
Henry PrestonWestern Diagnostics Pathology , Myaree, Perth, WA, Australia.
Arlene ChanBreast Cancer Research Centre-WA, Hollywood Private Hospital, Nedlands, WA, Australia; Curtin Medical School, Curtin University, Perth, WA, Australia.
Curtin University · AUPathwest Laboratory Medicine · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Historically, the immune environment was not considered an important target for breast cancer treatment. However, the association of lymphocytic infiltrates in triple negative and HER-2 over-amplified breast cancer subtypes with better outcomes, has provoked interest in evaluating the role of the immune system in the luminal B subtype that accounts for 39% of breast cancers and has a poor patient prognosis. It is unknown which immunosuppressive cell types or molecules (e.g., checkpoint molecules) are relevant, or where measurement is most informative. We hypothesize that a profound immunosuppressive tumor and/or lymph node milieu is prognostic and impacts on responses to therapies.

Indexed as

Anticancer immunitycheckpoint moleculesluminal B breast cancerpredictiveprognostic

Identifiers

PMID28405507
PMCPMC5384410
OpenAlexW2575016778

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.